2015-Q1-Update.pdf

Embed Size (px)

Citation preview

  • COMPANY UPDATEPT ENSEVAL PUTERA MEGATRADING TBK.

    Ended March 31, 2015 (Unaudited)

    Passion For Excellence:

    Creating ExcellenceThrough Innovation

  • TABLE OF CONTENT

    SECTION 1 Enseval In Brief 3

    SECTION 2 Business Overview 8

    SECTION 3 Operational Overview 20

    SECTION 4 Financial Overview 23

    SECTION 5 2015 Overview 28

  • SECTION 1ENSEVAL IN BRIEF

  • ENSEVAL IN BRIEF

    4

    Established in October 1973 with the aim of managing the distribution function because of theseparation of the distribution division from the marketing and production division of PT KalbeFarma;

    On 1 August 1994, the Company listed its shares on the Jakarta Stock Exchange; The Company focuses its activities on distribution and trading services under 5 divisions :

    Pharmaceutical products sales and distribution, which comprised of patented medicines aswell as generic medicines;

    Consumer products, non prescription medicine and nutrition sales and distribution; Medical equipment sales and distribution, which include marketing activities; Raw material sales and distribution, which include veterinary product; Healthcare services.

    Integrated healthcare Distribution and Logistic services company through Service Excellence, Technology Driven and Strong Leadership.

  • 51973 Incorporationof PT Enseval

    1988 Incorporationof PT Arya GuptaCempaka

    1993 PT Arya GuptaCempaka changed its name toPT Enseval PuteraMegatrading

    1994 PT Enseval PuteraMegatrading Tbk conductedits Initial Public Offering

    2003 Incorporationof PT MilleniaDharma Insani

    2007 Incorporation of PTEnseval Medika Prima andPT Global ChemindoMegatrading

    2008 Incorporation of PTRenalmed Tiara Utama

    2011 The CompanyRight Issue to financeexpansion

    2012 Obtained ISO9001:2008certification

    2013-2015 Makassar, Bandung, Bekasi, Jakarta 1, Kupang, Palu, Balikpapan, Bogor, Jember, RDCJakarta, RDC Surabaya, Palembang, Jakarta 2, Padang, Pematang Siantar, Tangerang, Yogyakarta,Batam, Bengkulu, Tasikmalaya, Semarang, and Surabaya 1 awarded BPOM awards these centresfor Good Distribution Practice in Pharmaceuticals.

    More than 40 years in business, Enseval constanly makes the best effort to obtain sustainable growth.

    ENSEVAL IN BRIEF

  • ENSEVAL IN BRIEF

    6

    Currently, the Company owns and operates 46 branches and 24 branches under subsidiaries, and 24sales office located on Indonesia achipelago;

    The Company also owns 2 Regional Distribution Center (RDC) located in Jakarta and Surabaya; For the information technology platform, the Company now is using Oracle E-Business Suite Release

    12; Until the end of December 2014, the Company's operation supported by over than 6,700 employees.

    Become Market Leader Through high quality of information Technology system and competent human resources.

  • AWARD & SERTIFICATION UNTIL MARCH 2015

    2015 OVERVIEW

    7

    ORACLE - EXA Trend-Setter Award.

    FRONTIER - The Best Building and Managing Corporate Image.

    FROST & SULLIVAN - Indonesia Pharmaceutical Distributor of the year.

    Department of Animal Husbandry in East Java province - the best distributor of veterinary drug.

    HERMINA HOSPITAL GROUP - The Best Pharmaceutical Distributor.

    BETHESDA HOSPITAL YOGYAKARTA - The Best Pharmaceutical Distributor.

    NIVEA - The Best Weighted Distributor.

    Rekor Bisnis Indonesia - Pharmaceutical Distributor with the Most Outlet Coverage.

    The Most Powerful Distribution Performance EXTRA JOSS

    KOMIX

  • 8 AZ/NZS ISO 9001:2008 Certified

    BS OHSAS 18001:2007 Certified

    Good Distribution Practices Certified

    Cara Distribusi Obat yang Baik (CDOB Certified)

    AWARD & SERTIFICATION UNTIL MARCH 2015

    2015 OVERVIEW

  • SECTION 2BUSINESS OVERVIEW

  • *Description of net sales per products as describe below :

    BUSINESS OVERVIEW

    NET SALES PER PRODUCTS UNTIL MARCH 31, 2015

    10

    Products Portfolio Net Sales (Rp)Contribution to Total Net

    Sales

    Consumer Products 1.704.266.238.982 41,82%

    Prescription Medicines 1.184.947.877.428 29,08%

    Non Prescription Medicines 697.104.357.456 17,11%

    Raw Materials 348.126.299.381 8,54%

    Medical Equipment 127.207.289.021 3,12%

    Veterinary Products 12.022.562.620 0,30%

    Health Care Services 1.451.445.616 0,03%

    Total : 4.075.126.070.504 100%

  • BUSINESS OVERVIEW

    DESCRIPTION OF NET SALES PER PRODUCTS AND THE CONTRIBUTION

    11

    41,82%29,08%

    17,11%

    8,54%

    3,12% 0,30% 0,04%Consumer Products

    Prescription Medicines

    Non Prescription Medicines

    Raw Materials

    Medical Equipment

    Veterinary Products

    Health Care Services

    Net SalesMarch 2015

    Rp4,075.1 billion

  • *Growth of net sales per products as describe below :

    BUSINESS OVERVIEW

    ALL BUSINESS LINE OF THE COMPANY WERE GREW SIGNIFICANTLY

    12

    Products PortfolioNet Sales March 2014

    (Rp)Net Sales March 2015

    (Rp)Growth

    Consumer Products 1.763.701.930.954 1.704.266.238.982 (3,37)%

    Prescription Medicines 1.146.345.285.055 1.184.947.877.428 3,37%

    Non Prescription Medicines 658.813.480.226 697.104.357.456 5,81%

    Raw Materials 331.202.664.581 348.126.299.381 11,86%

    Medical Equipment 90.870.076.053 127.207.289.021 39,99%

    Veterinary Products 10.693.056.284 12.022.562.620 12,43%

    Health Care Services 1.174879.724 1.451.445.616 23,54%

    Total : 3.982.801.372.877 4.075.126.070.504 2,32%

  • Total NetSales

    ConsumerProducts

    PrescriptionMedicines

    NonPrescriptionMedicines

    Raw Materials MedicalDevices

    VeterinaryProducts

    Health CareServices

    2014 2015

    3.37 %

    5.81 %

    11.86 %39.99 %

    BUSINESS OVERVIEW

    GROWTH OF NET SALES 2014 VS 2015

    13

    2.32 %

    12.43 % 23.54 %

    (3.37) %

  • BUSINESS OVERVIEW

    THE COMPANYS PRINCIPALS

    14

    Non-Prescription

    Prescription

    Consumer Health

  • BUSINESS OVERVIEW

    THE COMPANYS PRINCIPALS

    15

    Medical Device & Diagnostic

  • BUSINESS OVERVIEW

    THE COMPANYS PRINCIPALS

    16

    Raw material

  • RDC JAKARTARDC SURABAYA46 BRANCH24 BRANCH under subsidiaries (TSJ)24 SALES OFFICE

    BUSINESS OVERVIEWNATIONAL COVERAGE 70 FULL SERVICES BRANCHES & MORE THAN 200,000 DIRECT OUTLET COVERAGE

  • Type of outlet coveraged by the companys distribution

    Covers all trade channels in the market :

    BUSINESS OVERVIEW

    MORE THAN 200,000 DIRECT OUTLET COVERAGE

    18

    General / Traditional Trade Channel

    Wholesalers

    Retailers

    Provision Stores

    Convenience Stores

    Food & Beverage

    Store - Fruit Shops

    Cosmetic Stores

    etc

    Modern Trade Channel

    Hypermarkets

    Supermarkets

    Mini Markets

    Departement Stores

    etc

    Pharmaceutical Trade Channel

    Pharmacies

    Drugstores

    Hospitals

    Labs Clinics

    Institutions

    etc

  • 2015 OVERVIEW

    19

    SALES CONTRIBUTION BY CHANNEL (MARCH 2014 VS MARCH 2015)

    36,65%

    39,55%

    23,80%

    2015

    Pharmaceutical Trade General Trade

    Modern Trade

    40,37%

    31,66%

    27,97%

    2014

    Pharmaceutical Trade General Trade

    Modern Trade

  • 2015 OVERVIEW

    20

    SALES CONTRIBUTION BY PRINCIPAL (MARCH 2014 VS MARCH 2015)

    33%

    67%

    2014

    External Principal Internal Principal

    21%

    79%

    2015

    External Principal Internal Principal

  • BUSINESS OVERVIEW

    THE COMPANYS MODERN TRADE ACCOUNT

    21

  • BUSINESS OVERVIEW

    200,000+ DIRECT OUTLET COVERAGE

    22

    Pharmacy; 11.571

    Hospital; 1.614

    Drugstore; 4.485

    Wholesaler; 2.260

    Hypermarket, 178

    Supermarket; 1.179

    Minimarket; 3.115

    Provision Store; 162.000

    F&B Stores; 15.000

    Cosmetics; 1.750

    Others; 9.800

    Covers all trade channels in the market:

    - General / Traditional Trade Channel: Wholesalers, Retailers, Provision Stores, Convenience Stores, Food & Beverage Stores, Fruit Shops, Cosmetics Stores, etc

    - Modern Trade Channel: Hypermarkets, Supermarkets, Mini Markets, Department Stores, etc

    - Ethical Trade Channel: Pharmacies, Drugstores, Hospitals, Labs - Clinics, Institutions, etc

  • SECTION 3OPERATIONAL OVERVIEW

  • OPERATIONAL OVERVIEW

    24

    Mobile application (Tablet Computer & PDA)

    - Supervisor: Team Performance Analysis.

    - Salesman & Deliveryman: Faster Order Taking & Faster Information Process.

    Global Information System (GIS)

    - Application for more in depth sales and territory mapping.

    Supported by Enseval Customer Care (ECC)

    - In Branches Order Management, Complaint Handling, Basic Product Information.

    Customers also can reach Enseval office via Phone, Fax & Email for easy customer ordering.

    IT INFRASTRUCTURE

  • OPERATIONAL OVERVIEW

    25

    Centralized IT system using Oracle E-Business Solutions Integrated & Real Time system

    Use the best world-class ERP system by Oracle Complete Oracle E-Business SuiteOracle Warehouse Management System (WMS)Advance Supply Chain Planning (ASCP) and Oracle Demantra

    Tablet Computer & PDA system E-Mobile 2,300+ PDA used by Supervisors, Salesmen, Deliverymen, & Collectors Menu: Distribution Plan, Distribution Achievement, Overdue, etc

    Provide data security for antivirus by Trend Micro and Sonic Wall

    IT INFRASTRUCTURE

  • OPERATIONAL OVERVIEW

    26

    ENI (Enseval Net Info) Web based application

    Sales (hourly updated) & Stock (D-1)

    EXI (Enseval Xpress Info) SMS based application

    Sales & Stock Report

    ERI (Enseval Raw Data Info) Raw Data format, distribution and logistics information activities

    ENO (Enseval NET Order) Online order with business-to-business system

    For Principal

    For Customer

    COMPREHENSIVE BUSINESS ACCESS

  • SECTION 4FINANCIAL OVERVIEW

  • FINANCIAL OVERVIEW

    NET SALES GROWTH

    28

    3.982,80

    3.555,88

    4.075,13

    3.618,91

    2014 2015

    89.28%88.80%

    - 0.48%

    2.32%

    1.77%

    : Net Sales in Rp/billion : COGS in Rp/billion

    : Net Sales in Rp/billion : COGS in Rp/billion

    : COGS Margin

    Net Sales COGS

    March 31, 2014 (Unaudited)

    March 31, 2015 (Unaudited)

    March 31, 2014 (Unaudited)

    March 31, 2015 (Unaudited)

  • 426,92

    456,22

    FINANCIAL OVERVIEW

    EXPENSE RATIO

    29

    6.86%

    March 31, 2014 (Unaudited)

    March 31, 2015 (Unaudited)

    Gross Profit

    Gross Profit Margin

    Gross Profit (Rp/Billion)

    10.72%11.20%0.48%

    318,80

    335,35

    5.19%

    March 31, 2014 (Unaudited)

    March 31, 2015 (Unaudited)

    Operational Expense

    Operational Expense Margin

    Operational Expense (Rp/Billion)

    8.00%8.23%0.22%

  • FINANCIAL OVERVIEW

    PROFIT GROWTH (MARCH 2014 VS MARCH 2015)

    30

    108,12 122,74 85,85120,87 130,63

    95,45

    11.79% 6.43%11.19%

    Operating Profit Margin Income Before Tax Expense Margin

    Income For The Year Margin

    March 31, 2014 (Unaudited)

    March 31, 2015 (Unaudited)

    March31, 2014 (Unaudited)

    March 31, 2015 (Unaudited)

    March 31, 2014 (Unaudited)

    March 31, 2015 (Unaudited)

    2.71%2.97%0.26%

    Operating Profit(Rp/Billion)

    Income Before Tax Expense (Rp/Billion)

    Operating Profit Income Before Tax Expense Income For The Year

    3.08% 3.21%0.13%

    2.16%2.34%0.18%

  • FINANCIAL OVERVIEW

    FINANCIAL POSITION (DEC 2014 VS MARCH 2015)

    31

    6.190,62

    2.640,743.549,88

    6.164,52

    2.517,543.646,98

    0.42%

    4.67%

    2.74%

    Dec 31, 2014 (Audited)

    March 31, 2015 (Unaudited)

    Total Assets (Rp/Billion) Total Liabilities (Rp/Billion)

    Dec 31, 2014 (Audited)

    March 31, 2015 (Unaudited)

    Dec 31, 2014 (Audited)

    March 31, 2015(Unaudited)

  • SECTION 52015 OVERVIEW

  • WAREHOUSE MANAGEMENT SYSTEM-Oracle-based WMS

    -Manage stock from

    inbound-outbound, by location, SKU, Batch Number, Expiry Date.

    -Bar-coding system with mobile bar-code reader to eliminate duplication & increase accurate operation.

  • COLD CHAIN MANAGEMENT-Enseval has implemented and Standardized Cold Chain Management in its RDC, Branch Warehouse, and Transportation according to ISO 9001:2008.

    -Cold Chain Management is performed with close control

    -All activities is always recorded and stored properly

    Cold Chain Handling in Enseval Delivery with Temperature Controlled Transportation

    Temperature MonitoringDocument

  • STANDARDIZED FACILITIESSTANDARDIZED BRANCHES (FULL SERVICES)

  • STRATEGIC VALUE TO BUSINESS PARTNERS Strong product portfolio.

    Sustainable business growth.

    Supported by 2 RDC, 46 branches, 24 Sales Office, & 200,000+ direct coverage outlets.

    Market Leading Position in Indonesia

    40+ years of strategic expertise in distribution and logistics service.

    Strong and good relationship with all business players : Principals & Outlets.

    Having in aggregate over 100 years of experience senior management team and supported by more than 5000 employees.

    Reliable Partner to Grow

    Public listed company with professional management that treats all business partners equally with the utmost transparency and accountability.

    Independent business entity with neutrality to ensure fairness to all stakeholders.Transparency and Neutrality

    Robust balance sheet figures.

    Solid financial performance.Strong Financial Track Record

    Commitment to assist & support Principal to achieve its goals.

    Implementation of Continuous Improvement (CONIM) in all business aspects by Ensevals employees in every level.

    Ensevals Commitment Towards Improvement

  • FORWARD LOOKING STATEMENTThis presentation has been prepared for informational purposes only by PT Enseval Putera Megatrading Tbk. ("Enseval" or the "Company")

    This presentation has been prepared solely for use in connection with the release 0f 31 March 2015 unaudited results of the Company. The informationcontained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and noreliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company orany of their respective affiliates, and their respective commissioners, directors and employees, advisors or representative shall have any liability whatsoever (innegligence or otherwise) for any loss however arising from any use of this presentation or its contents or otherwise arising in connection with the presentation.Any decision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation.The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or anexemption from registration.This presentation and its contents are confidential unless they are become generally avaiable as public information in accordance with prevailing lawsregulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by receipentsto any other person. This presentation does not constitute a recommendation regarding the securities of the Company.This presentation, including the information and opinions contained herein, is provided as the date of this presentation and is subject to change without notice,including change as a result of the issuance of 31 March 2015 unaudited results of the Company.This presentation includes "forward-looking statements". These statements contain the words "anticipate", "believe", "intend", "estimate", "expect" and wordsof similiar meaning. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding theCompany's financial position, business strategy, plans and objectives of management for future operations (including development plans, objectives relating tothe Company's products and services and anticipated product launches) are forward-looking statements. Such forward-looking statements are based onnumerous assumptions regarding the Company's present and future business strategies and the environment in which of the Company will operate in thefuture. These forward-looking statements speak only ast the date of this presentation. The Company expressly disclaims any obligation or reflection of anychange in the Company's expectations with regard thereto, or any change in events, conditions or circumtances on which any statements is based.Market data and certain industry forecast used in this presentation were obtained from market research, publicity avaiable information and industrypublications which have not been independently verified, and no presentation is made as to the accuracy of such information.

  • THANK YOUFor Further Information:

    Corporate SecretaryPT Enseval Putera Megatrading Tbk.Enseval BuildingKawasan Industri PulogadungJalan Pulolentut No. 10Jakarta 13920 IndonesiaPhone : 62-21-46822422 Fax : 62-21-4609039Website : www.enseval.comEmail : [email protected]